Diagnostic News and Research

RSS

Strategic Diagnostics is now SDIX

Strategic Diagnostics Inc., a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic, and food safety applications, today announced it will be doing business as SDIX (Strategic Diagnostics Inc. d/b/a SDIX).

11 Feb 2010

Today's OpEds: Prescriptions for health reform

The best ideas out there are not those that were passed by the House and Senate last year, which consist of more spending, more regulations and more bureaucracy. If the president is serious about building a system that delivers more quality choices at lower cost for every American, here's where he should start (Newt Gingrich and John C. Goodman, 2/10).

11 Feb 2010

FDA to take closer look at medical radiation, devices

The Food and Drug Administration will step up oversight of three forms of medical radiation, including CT scans, in an effort to reduce patients' exposure to unnecessary radiation, The New York Times reports.

11 Feb 2010

Mental health 'bible' starts revamp with new terminology, diagnoses

The Wall Street Journal: "Mental-health experts wrestling with how to fit temper tantrums, hoarding and even Internet addiction into the current understanding of mental illness are proposing changes to the field's primary reference for diagnoses for the first time in 16 years. The draft revisions of the Diagnostic and Statistical Manual of Mental Disorders—the bible for mental health clinicians and researchers—unveiled Wednesday could have effects that ripple through mental health care."

11 Feb 2010

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

The Catalysis Foundation for Health (Catalysis), a 501 (c) (3) non-profit entity dedicated to developing sustainable diagnostics for the developing world, announced today that it has received a $5 million grant from the Bill & Melinda Gates Foundation. The grant money will be used to discover new tuberculosis (TB) biomarkers that can be used to improve diagnostic tests and potentially develop more effective TB treatments.

10 Feb 2010

Goodwin Biotechnology, Macrocyclics announce collaboration on Chelation and Bioconjugation

Goodwin Biotechnology Inc., a full service Contract Biomanufacturing Company and Macrocyclics, Inc., a manufacturer of customized chelating agents, jointly announced today their collaborative agreement on Chelation and Bioconjugation. The collaboration will strengthen joint customer projects in Nuclear Medicine involving Chelation, Bioconjugation and GMP manufacturing.

10 Feb 2010

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ open new path to femtomedicine

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ has opened up the path to femtomedicine, an entirely new cancer diagnostics, it was reported today at First Global Congress on NanoEngineering for Medicine and Biology in Houston, TX.

10 Feb 2010

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.

10 Feb 2010

Renowned experts explore latest key development in nuclear medicine and molecular imaging at 2010 SNM summit

Educators, researchers, physicians, technologists and medical experts from across the country converged on Albuquerque, N.M., last week to explore topics in nuclear medicine, molecular imaging, nanomedicine and clinical trials during SNM's 2010 Conjoint Mid-Winter Meetings.

10 Feb 2010

Autism Speaks: Ten most significant autism research achievements in 2009

Autism Speaks, the world's largest autism science and advocacy organization has released its annual list of the 10 most significant research achievements to have impacted autism during the previous year. Every year, Autism Speaks documents the progress made toward its mission to discover the causes and treatment for autism spectrum disorders, and compiles a list of the 10 most significant research achievements to have impacted autism during the previous year.

10 Feb 2010

Sequenom CMM licenses rights from Optherion to develop and commercialize AMD diagnostic tests

Sequenom, Inc., today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).

10 Feb 2010

TBTC to receive more than $90 million to develop effective tuberculosis treatments

The Tuberculosis Trials Consortium (TBTC) strives to conduct research about the diagnosis, medical treatment, and prevention of tuberculosis (TB) infection and disease. The network is composed of a partnership of clinical investigators from the U.S. Centers for Disease Control and Prevention (CDC), public health departments from different countries, as well as medical and pharmaceutical institutions.

10 Feb 2010

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses.

10 Feb 2010

APA releases proposed draft diagnostic criteria for DSM-5

The American Psychiatric Association today released the proposed draft diagnostic criteria for the fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM). The draft criteria represent content changes under consideration for DSM, which is the standard classification of mental disorders used by mental health and other health professionals, and is used for diagnostic and research purposes.

10 Feb 2010

Data provide key information about epigenetic profiles for gastric cancer

Gastric cancer, one of the most common types of cancer, is associated with high mortality rates. In the last decades, a decrease in the worldwide incidence has been observed with some changes in the therapeutic and diagnostic options.

10 Feb 2010

FDA announces initiative to reduce cancer risk from medical imaging procedures

The U.S. Food and Drug Administration today announced an initiative to reduce unnecessary radiation exposure from three types of medical imaging procedures: computed tomography (CT), nuclear medicine studies, and fluoroscopy.

10 Feb 2010

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.

10 Feb 2010

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

The National Institute of Allergies and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a five-year contract totaling $15,254,919 to Tulane University for its ongoing efforts to treat and prevent Lassa fever, an often deadly viral disease that threatens hundreds of thousands of people annually in West Africa and is classified as a potential bioterrorism threat.

10 Feb 2010

Ikonisys to showcase oncoFISH cervical test at Eurogin 2010 Cervical Cancer Prevention Conference

Ikonisys announced today that they will exhibit their proprietary oncoFISH® cervical test at the Eurogin 2010 Cervical Cancer Prevention Conference held at the Grimaldi Forum in Monte Carlo from February 17-20.

10 Feb 2010

MHI researchers receive $4.8M as grants for genetics and genomic medicine research projects

Two research teams led by Dr. Christine Des Rosiers and Dr. John D. Rioux, both researchers at the Montreal Heart Institute (MHI) and professors at the Universit- de Montr-al, have been awarded grants of $2.5 million and $2.3 million, respectively, to finance research projects on genetics and genomic medicine.

10 Feb 2010

Diagnostic News and Research

Strategic Diagnostics is now SDIX

Today's OpEds: Prescriptions for health reform

FDA to take closer look at medical radiation, devices

Mental health 'bible' starts revamp with new terminology, diagnoses

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

Goodwin Biotechnology, Macrocyclics announce collaboration on Chelation and Bioconjugation

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ open new path to femtomedicine

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Renowned experts explore latest key development in nuclear medicine and molecular imaging at 2010 SNM summit

Autism Speaks: Ten most significant autism research achievements in 2009

Sequenom CMM licenses rights from Optherion to develop and commercialize AMD diagnostic tests

TBTC to receive more than $90 million to develop effective tuberculosis treatments

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

APA releases proposed draft diagnostic criteria for DSM-5

Data provide key information about epigenetic profiles for gastric cancer

FDA announces initiative to reduce cancer risk from medical imaging procedures

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

Ikonisys to showcase oncoFISH cervical test at Eurogin 2010 Cervical Cancer Prevention Conference

MHI researchers receive $4.8M as grants for genetics and genomic medicine research projects

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News